Morgan Stanley Reiterates Overweight on Biogen Idec Following AlphaWise Survey
May 03, 2013 at 09:14 AM EDT
In a report published Friday, Morgan Stanley analyst Marshall Urist reiterated an Overweight rating on Biogen Idec (NASDAQ: BIIB ). In the report, Urist noted, “Our AlphaWise survey of 121 neurologists in the US and Europe (performed in the month prior to Tecfidera approval) supports a strong launch, $4B+ in
